Herb Bowers

Wir sind bis zum ersten Quartal 2025 vollständig finanziert, um die Ergebnisse der Blindstudie abzuwarten. Eine große Anzahl von Patienten befindet sich noch in der Testphase, was laut CEO ermutigend ist. Wir befinden uns daher in den letzten Monaten.

Nothing at all

Do your homework…on the market size, not some random sp multiple.

It’s really not difficult to estimate valuation of a company with a new anthracycline low in cardio toxicity across a whole range of indicators leading with an FDA acknowledged proof of concept AML indication. The market data is readily out there and if anything, understated because of the lifetime maximums and dose limits on current chemotherapy due to severe adverse effects. The numbers are staggering, run them yourself! The process protection patents and core patent licensed make it even more compelling. You’ve got an industry renowned medical adviser on staff to help market to his peers to boot. I continue to think they will sell and never personally conduct this protracted miracle trial and the funding/dilution is a mechanism to load up the insiders prior to that. IMO

Tutes are increasing positions slightly- always a good sign

1. The shares to fund trial through Q1 will yield approximately 26m shares outstanding as registered, not 30m but either way, that’s what lures the clueless into this market in the short term.
2. I would expect a decision from DSMB to occur before any concern on the <$1 listing parameter which should negate any r/s need IMO
3. The trial remains blinded from every one so nobody knows including management and as we approach the final stretch, they have been able to keep the interest of investors which I applaud as much as the brilliant trial design itself. I hope for the best after analyzing as much publicity available info as available

$1500 IMO

Thursday?

Conference BEGINS TODAY AT 1PM EASTERN. CNS PHARMACEUTICALS is TONIGHTST 9:15ET IN DENVER

My belief is I wouldn’t show my face at a prestigious conference like today’s and show bad news on patient safety and efficacy